Inclusion Criteria:  Adults over 19 years old on the day of consent Pathologically confirmed solid cancer Patients with advanced or metastatic solid timour failed or tolerable with standard therapy. A person who has a tumor lesion that can safely undergo tissue biopsy during administration of the test drug and can provide tissues stored at the clinical trial agency or tissue obtained from a tissue biopsy conducted before the first administration of the test drug  Exclusion Criteria:  Those who have been treated with IL-2 or TGF-β inhibitors other than test drugs (e.g., anti-sense oligonucleotide, antibody, TGF-b receptor inhibitor) Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment. Immunotherapy within 2 weeks prior to first dose of study treatment. Major surgery within 4 weeks prior to first dose of study treatment.